In a nutshell This article looked at the effectiveness and safety of continuous ixazomib (Ninlaro), thalidomide (Thalomid), and dexamethasone (Decadron) (ITd) in the treatment of relapsed and/or refractory (RR) multiple myeloma (MM). The authors found that this regimen was well tolerated and showed promising effectiveness in the treatment of...
Read More
In a nutshell This study reported the use of autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). The data showed improved outcomes in patients that received ASCT compared to those who did not. Some background MM is a cancer of plasma cells (myeloma cells). One therapeutic option is high-dose melphalan...
Read More
In a nutshell This article reviewed different treatment options for multiple myeloma (MM)-related bone disease. Some background MM is a type of cancer of the bone marrow that can lead to abnormal immune cells. Up to 80% of newly diagnosed patients develop bone disease. These patients have a high risk of bone problems, such as fractures and...
Read More
In a nutshell This trial was carried out to compare bortezomib (Velcade; V) and carfilzomib (Kyprolis; K) in combination with Cd (cyclophosphamide and dexamethasone) as second line treatment in patients with relapsed multiple myeloma (MM). The authors found the KCd is as effective as VCd and K can also be used as a maintenance treatment in these...
Read More
In a nutshell This study evaluated the treatments and long-term outcomes of older and unfit patients with newly diagnosed multiple myeloma (MM). The authors concluded that first-line therapies vary widely among patients, and high-risk patients may receive less effective treatment. Some background MM is a type of cancer of the bone marrow that can...
Read More
In a nutshell This study investigated the effectiveness and safety of different regimens containing pegylated liposomal doxorubicin (PLD; Doxil) for patients with newly diagnosed multiple myeloma (NDMM). The data showed that the different PLD treatment regimens had promising effectiveness with manageable side effects. Some background Multiple...
Read More
In a nutshell The aim of this study was to evaluate the addition of isatuximab (Sarclisa) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with relapsed/refractory (r/r) multiple myeloma (MM). The study found that patients who were given isatuximab had a better outcome. Some background MM is a type of blood cancer...
Read More
In a nutshell The aim of this study was to evaluate the safety and effectiveness of adding selinexor (X; Xpovio) to the Vd (bortezomib and dexamethasone) regimen in older, frail patients with multiple myeloma (MM). The study found that the addition of selinexor to Vd (XVd) was safe and gave older, more frail patients a better...
Read More
In a nutshell This study evaluated the clinical effectiveness and safety of daratumumab (Darzalex) treatment for patients with heavily pre-treated multiple myeloma (MM) in a real-world setting. The study showed that daratumumab is safe and effective in these patients. Some background MM is a type of cancer that affects white blood...
Read More
In a nutshell The aim of this study was to evaluate the long-term safety and effectiveness of adding daratumumab (Darzalex) to RVd (lenalidomide/bortezomib/dexamethasone) therapy, followed by D-R (daratumumab/lenalidomide) maintenance for patients with newly diagnosed multiple myeloma (MM). The study found that this treatment was well tolerated...
Read More
In a nutshell This study investigated the effectiveness and safety of combining vorinostat (Zolinza) with bortezomib (Velcade) and dexamethasone (Decadron) in patients with relapsed multiple myeloma (MM). The data showed that the treatment combination had promising effectiveness but with side effects. Some background Multiple...
Read More
In a nutshell The aim of this study was to evaluate if the VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) regimen in combination with immunotherapy was effective as a salvage therapy for patients with relapsed or refractory (r/r) multiple myeloma (MM). The study found this salvage therapy option...
Read More
